These sales are routine and non-informative, both insiders sold in conjunction with option exercises, a pattern consistent with tax withholding or diversification. The dollar amount is negligible relative to market cap. No action warranted; monitor for any change in pattern (e.g., C-suite open-market selling without option exercise) or a material corporate event that could alter the read.
ALKS drugs
ALKS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $41.19entry
- T+1 · 6mo ago +3.69%α +4.41% · $42.71
- T+5 · 5mo ago +7.53%α +10.50% · $44.29
- T+20 · 5mo ago +25.57%α +27.39% · $51.72
- T+60 · 3mo ago +19.36%α +18.50% · $49.16
Price Chart
How similar events traded
Executive Summary
Two Alkermes insiders, the Chief Medical Officer and the Interim Principal Accounting Officer, sold a combined $1.06M in open-market sales over a 4-day window, with the CMO also exercising stock options. The total sales represent ~0.015% of the $7.0B market cap, well below the 0.1% materiality threshold, and the CMO's sale is paired with a same-day option exercise, suggesting a tax- or liquidity-driven transaction rather than a bearish signal. No material corporate event (earnings, guidance, M&A) accompanies these routine sales.
Key Financial Metrics
Key Facts
- Total insider sales of $1.06M represent ~0.015% of Alkermes' $7.0B market cap, trivial by proportionality standards.
- CMO Hopkinson sold 9,000 shares ($375K) on June 1, simultaneously exercising 10,000 derivative shares (5,000 at $0, 5,000 at $19.34), a classic cashless exercise pattern.
- Interim PAO Parisi sold 16,217 shares ($687K) on May 29, paired with exercise of 6,784 derivative shares, also consistent with a cashless exercise.
- No open-market purchases were made by any insider in the cluster window.
- Prior 30-day insider activity was limited to $1.1M in sales, no unusual acceleration or change in pattern.
Financial Impact
Total insider sales of $1.06M, or ~0.015% of market cap, immaterial.
Risk Factors
- If a material adverse event (e.g., clinical trial failure, FDA setback) emerges in the coming weeks, these sales could be viewed as opportunistic in hindsight.
- The CMO's sale is the first disclosed trade in the filing window, a larger cluster of C-suite open-market sales without option exercises would be more concerning.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ALKS-1780356434266 |
Track record
23 reports on ALKS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
- Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers